VOYAGER THERAPEUTICS
Live / Applied — First extension granted (statement of use) (as of 04 Feb 2026)
What this means for you
Not registered yet, but its 18 Aug 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98140452
- Mark type
- Design + words
- Filed
- 18 Aug 2023
- Published for opposition
- 17 Jun 2025
- Attorney of record
- Keith Toms, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; antibody and gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via antibody, gene replacement, gene knockdown, or vectorized antibodies; antibody and gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; Drug delivery agents comprising capsids viral platforms, and non-viral platforms, that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; pharmaceutical for the treatment of neurodegenerative diseases and diseases of the central nervous system, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, Huntington's disease, and prion disease
- Class 042 — Scientific and technological services: Biotechnology research services; research and development of platform technologies for delivery of therapies; research and development of platform technologies for delivery of gene therapies, antibody therapies and pharmaceuticals; research and development regarding the use of RNA-based functional screening platforms to discover, research and develop novel capsids for genetic delivery of therapies and pharmaceuticals; Pharmaceutical research and development in the field of gene therapy and antibody therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy and antibody therapy; pharmaceutical research services; research and development of pharmaceutical preparations for non-viral and gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development in the pharmaceutical and biotechnology fields; research and development regarding the delivery of therapies across the blood-brain barrier; research and development regarding the non-viral and viral vectors for the delivery of therapeutic agents; research and development regarding the identification and targeting of specific cells and tissues for gene therapy; providing scientific research information in the field of clinical trials; hosting a website featuring medical research information
- Class 044 — Medical, beauty and agricultural services: Medical services provided for clinical trials; providing patient care for clinical trials; providing medical information in the field of gene therapy; providing a website featuring medical information; medical treatment of neurological diseases, neurodegenerative diseases, and diseases of the central nervous system, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, and Huntington's disease, and prion disease
- Class 045 — Legal and security services: Collaboration services in the field of platform technologies for delivery of therapies and pharmaceuticals, namely, licensing of intellectual property
Owner
- Voyager Therapeutics, Inc., Lexington, MA, US
- Voyager Therapeutics, Inc., Lexington, MA, US
Prosecution history
- 04 Feb 2026 — SOU EXTENSION 1 GRANTED
- 04 Feb 2026 — SOU EXTENSION 1 FILED
- 04 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Jun 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Jun 2025 — PUBLISHED FOR OPPOSITION
- 11 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Apr 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
- 23 Sept 2024 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 23 Sept 2024 — LETTER OF SUSPENSION E-MAILED
- 23 Sept 2024 — SUSPENSION LETTER WRITTEN
- 19 Sept 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 19 Sept 2024 — EXAMINERS AMENDMENT E-MAILED
- 19 Sept 2024 — EXAMINERS AMENDMENT -WRITTEN